Pulmonary hypertension complicating connective tissue disease

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 5, 2013, Pages 581-599

  Lynch, Josephp ^a   Belperio, Johna ^a   Saggar, Rajeev ^b   Fishbein, Michaelc ^a   Saggar, Rajan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

connective tissue disease; pulmonary arterial hypertension; pulmonary hypertension; scleroderma; systemic sclerosis

Indexed keywords

AMBRISENTAN; AUTOANTIBODY; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CARBON MONOXIDE; CELL ADHESION MOLECULE; CENTROMERE PROTEIN A; CENTROMERE PROTEIN B; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; HEMOGLOBIN; IMATINIB; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; RNA POLYMERASE; SILDENAFIL; SITAXSENTAN; VASCULOTROPIN; WARFARIN;

ARTICLE; DERMATOMYOSITIS; DISEASE DURATION; DISEASE SEVERITY; DRUG MEGADOSE; EARLY DIAGNOSIS; EXERCISE; FOLLOW UP; FORCED VITAL CAPACITY; HEART CATHETERIZATION; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HEREDITY; HUMAN; HYPERALIMENTATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTERSTITIAL LUNG DISEASE; LUNG BLOOD VESSEL; LUNG TRANSPLANTATION; MONOTHERAPY; MORTALITY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PSEUDOOBSTRUCTION; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; QUALITY OF LIFE; RISK FACTOR; SCLERODERMA; SEDIMENTATION RATE; SURVIVAL RATE; SYSTEMIC SCLEROSIS; TREATMENT DURATION; TREATMENT FAILURE;

ANTIHYPERTENSIVE AGENTS; CONNECTIVE TISSUE DISEASES; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; LUNG TRANSPLANTATION; PHENYLPROPIONATES; PHOSPHODIESTERASE 5 INHIBITORS; PROGNOSIS; PYRIDAZINES; RECEPTORS, ENDOTHELIN; SCLERODERMA, SYSTEMIC; SULFONAMIDES;

EID: 84884271199     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0033-1356547     Document Type: Article

References (235)

1. Badesch D. B., Tapson V. F., McGoon M. D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med: 2000; 132 6 425 434
2. Kuhn K. P., Byrne D. W., Arbogast P. G., Doyle T. P., Loyd J. E., Robbins I. M. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med: 2003; 167 4 580 586
3. Trad S., Amoura Z., Beigelman C., et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum: 2006; 54 1 184 191
4. Launay D., Sitbon O., Le Pavec J., et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford): 2010; 49 3 490 500
5. Condliffe R., Kiely D. G., Peacock A. J., et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med: 2009; 179 2 151 157
6. Wigley F. M., Lima J. A., Mayes M., McLain D., Chapin J. L., Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum: 2005; 52 7 2125 2132
7. Sanchez O., Sitbon O., Jaïs X., Simonneau G., Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest: 2006; 130 1 182 189
8. Tanaka E., Harigai M., Tanaka M., Kawaguchi Y., Hara M., Kamatani N. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol: 2002; 29 2 282 287
9. Li E. K., Tam L. S. Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol: 1999; 26 9 1923 1929
10. Chung S. M., Lee C. K., Lee E. Y., Yoo B., Lee S. D., Moon H. B. Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol: 2006; 25 6 866 872
11. Simonson J. S., Schiller N. B., Petri M., Hellmann D. B. Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol: 1989; 16 7 918 925
12. Hunzelmann N., Genth E., Krieg T., et al. Registry of the German Network for Systemic Scleroderma. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford): 2008; 47 8 1185 1192
13. Gabrielli A., Avvedimento E. V., Krieg T. Scleroderma. N Engl J Med: 2009; 360 19 1989 2003
14. Ferri C., Valentini G., Cozzi F., et al. Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore): 2002; 81 2 139 153
15. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum: 1980; 23 5 581 590
16. LeRoy E. C., Black C., Fleischmajer R., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol: 1988; 15 2 202 205
17. Denton C. P., Hachulla E. Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening. Eur Respir Rev: 2011; 20 122 270 276
18. Steen V. D., Conte C., Owens G. R., Medsger T. A. Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum: 1994; 37 9 1283 1289
19. Meyer O. C., Fertig N., Lucas M., Somogyi N., Medsger T. A. Jr. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol: 2007; 34 1 104 109
20. Mayes M. D., Lacey J. V. Jr, Beebe-Dimmer J., et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum: 2003; 48 8 2246 2255
21. Mukerjee D., St George D., Coleiro B., et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis: 2003; 62 11 1088 1093
22. Steen V. Advancements in diagnosis of pulmonary arterial hypertension in scleroderma. Arthritis Rheum: 2005; 52 12 3698 3700
23. Hachulla E., Gressin V., Guillevin L., et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum: 2005; 52 12 3792 3800
24. Hachulla E., de Groote P., Gressin V., et al. Itinér AIR-Sclérodermie Study Group. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum: 2009; 60 6 1831 1839
25. Launay D., Mouthon L., Hachulla E., et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol: 2007; 34 5 1005 1011
26. Vonk M. C., Broers B., Heijdra Y. F., et al. Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study. Ann Rheum Dis: 2009; 68 6 961 965
27. Hachulla E., Carpentier P., Gressin V., et al. ItinérAIR- Sclérodermie Study Investigators. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR- Sclérodermie study. Rheumatology (Oxford): 2009; 48 3 304 308
28. Ioannidis J. P., Vlachoyiannopoulos P. G., Haidich A. B., et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med: 2005; 118 1 2 10
29. Steen V. D., Medsger T. A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis: 2007; 66 7 940 944
30. Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol: 2010; 37 1 42 53
31. Sato H., Lagan A. L., Alexopoulou C., et al. The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis Rheum: 2004; 50 2 558 564
32. Weiner E. S., Earnshaw W. C., Senécal J. L., Bordwell B., Johnson P., Rothfield N. F. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum: 1988; 31 3 378 385
33. Joyal F., Choquette D., Roussin A., Levington C., Senécal J. L. Evaluation of the severity of systemic sclerosis by nailfold capillary microscopy in 112 patients. Angiology: 1992; 43 3 Pt 1 203 210
34. Maricq H. R., Spencer-Green G., LeRoy E. C. Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis. Am J Med: 1976; 61 6 862 870
35. LeRoy E. C., Medsger T. A. Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol: 2001; 28 7 1573 1576
36. Hachulla E., Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol: 2011; 40 2 78 83
37. Steen V. D., Medsger T. A. Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum: 2000; 43 11 2437 2444
38. Sacks D. G., Okano Y., Steen V. D., Curtiss E., Shapiro L. S., Medsger T. A. Jr. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. J Rheumatol: 1996; 23 4 639 642
39. Penn H., Howie A. J., Kingdon E. J., et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM: 2007; 100 8 485 494
40. Poormoghim H., Lucas M., Fertig N., Medsger T. A. Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum: 2000; 43 2 444 451
41. Yousem S. A. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol: 1990; 21 5 467 474
42. Mayes M. D. Scleroderma epidemiology. Rheum Dis Clin North Am: 2003; 29 2 239 254
43. Chifflot H., Fautrel B., Sordet C., Chatelus E., Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum: 2008; 37 4 223 235
44. Le Guern V., Mahr A., Mouthon L., Jeanneret D., Carzon M., Guillevin L. Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology (Oxford): 2004; 43 9 1129 1137
45. Barnes J., Mayes M. D. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol: 2012; 24 2 165 170
46. Satoh M., Akizuki M., Kuwana M., et al. Genetic and immunological differences between Japanese patients with diffuse scleroderma and limited scleroderma. J Rheumatol: 1994; 21 1 111 114
47. Nishioka K., Katayama I., Kondo H., et al. Scleroderma Research Committee Japan. Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc). J Dermatol: 1996; 23 10 677 682
48. Hashimoto A., Endo H., Kondo H., Hirohata S. Clinical features of 405 Japanese patients with systemic sclerosis. Mod Rheumatol: 2012; 22 2 272 279
49. Reveille J. D., Fischbach M., McNearney T., et al. GENISOS Study Group. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum: 2001; 30 5 332 346
50. Agarwal S. K., Tan F. K., Arnett F. C. Genetics and genomic studies in scleroderma (systemic sclerosis). Rheum Dis Clin North Am: 2008; 34 1 17 40, v
51. Loubière L. S., Lambert N. C., Madeleine M. M., et al. HLA allelic variants encoding DR11 in diffuse and limited systemic sclerosis in Caucasian women. Rheumatology (Oxford): 2005; 44 3 318 322
52. Bryan C., Knight C., Black C. M., Silman A. J. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum: 1999; 42 12 2660 2665
53. Simeón C. P., Armadans L., Fonollosa V., et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford): 2003; 42 1 71 75
54. Lee P., Langevitz P., Alderdice C. A., et al. Mortality in systemic sclerosis (scleroderma). Q J Med: 1992; 82 298 139 148
55. Jacobsen S., Ullman S., Shen G. Q., Wiik A., Halberg P. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol: 2001; 28 11 2454 2459
56. Hesselstrand R., Scheja A., Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis: 1998; 57 11 682 686
57. Bryan C., Howard Y., Brennan P., Black C., Silman A. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol: 1996; 35 11 1122 1126
58. Nagy Z., Czirják L. Predictors of survival in 171 patients with systemic sclerosis (scleroderma). Clin Rheumatol: 1997; 16 5 454 460
59. Scussel-Lonzetti L., Joyal F., Raynauld J. P., et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore): 2002; 81 2 154 167
60. Steen V. D., Costantino J. P., Shapiro A. P., Medsger T. A. Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med: 1990; 113 5 352 357
61. Tyndall A. J., Bannert B., Vonk M., et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis: 2010; 69 10 1809 1815
62. Bond C., Pile K. D., McNeil J. D., et al. South Australian Scleroderma Register: analysis of deceased patients. Pathology: 1998; 30 4 386 390
63. Kuwana M., Kaburaki J., Okano Y., Tojo T., Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum: 1994; 37 1 75 83
64. Barnett A. J., Miller M. H., Littlejohn G. O. A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol: 1988; 15 2 276 283
65. Kuwana M., Kaburaki J., Arnett F. C., Howard R. F., Medsger T. A. Jr, Wright T. M. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum: 1999; 42 3 465 474
66. Steen V. D., Medsger T. A. Jr, Osial T. A. Jr, Ziegler G. L., Shapiro A. P., Rodnan G. P. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med: 1984; 76 5 779 786
67. Steen V. D., Powell D. L., Medsger T. A. Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum: 1988; 31 2 196 203
68. Reveille J. D., Solomon D. H. American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum: 2003; 49 3 399 412
69. Fanning G. C., Welsh K. I., Bunn C., Du Bois R., Black C. M. HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients. Br J Rheumatol: 1998; 37 2 201 207
70. Dick T., Mierau R., Bartz-Bazzanella P., et al. Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis. Ann Rheum Dis: 2002; 61 2 121 127
71. Hesselstrand R., Scheja A., Shen G. Q., Wiik A., Akesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford): 2003; 42 4 534 540
72. Okano Y., Steen V. D., Medsger T. A. Jr. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum: 1992; 35 1 95 100
73. Mitri G. M., Lucas M., Fertig N., Steen V. D., Medsger T. A. Jr. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum: 2003; 48 1 203 209
74. Ho K. T., Reveille J. D. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther: 2003; 5 2 80 93
75. Dagher J. H., Scheer U., Voit R., et al. Autoantibodies to NOR 90/hUBF: longterm clinical and serological followup in a patient with limited systemic sclerosis suggests an antigen driven immune response. J Rheumatol: 2002; 29 7 1543 1547
76. Franceschini F., Cavazzana I., Generali D., et al. Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients. J Rheumatol: 2002; 29 7 1393 1397
77. Rozman B., Cucnik S., Sodin-Semrl S., et al. Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study. Ann Rheum Dis: 2008; 67 9 1282 1286
78. Fertig N., Domsic R. T., Rodriguez-Reyna T., et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum: 2009; 61 7 958 965
79. Negi V. S., Tripathy N. K., Misra R., Nityanand S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol: 1998; 25 3 462 466
80. Wusirika R., Ferri C., Marin M., et al. The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma. Am J Clin Pathol: 2003; 120 4 596 606
81. Pope J. E., Thompson A. The frequency and significance of anticardiolipin antibodies in scleroderma. J Rheumatol: 2000; 27 6 1450 1452
82. Baroni S. S., Santillo M., Bevilacqua F., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med: 2006; 354 25 2667 2676
83. Hietarinta M., Lassila O., Hietaharju A. Association of anti-U1RNP- and anti-Scl-70-antibodies with neurological manifestations in systemic sclerosis (scleroderma). Scand J Rheumatol: 1994; 23 2 64 67
84. Walker U. A., Tyndall A., Czirják L., et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis: 2007; 66 6 754 763
85. Silman A. J. Scleroderma and survival. Ann Rheum Dis: 1991; 50 4 267 269
86. Okano Y., Steen V. D., Medsger T. A. Jr. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med: 1993; 119 10 1005 1013
87. Steen V. D. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum: 2005; 35 1 35 42
88. Marguerie C., Bunn C. C., Copier J., et al. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore): 1992; 71 6 327 336
89. Dib H., Tamby M. C., Bussone G., et al. Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Eur Respir J: 2012; 39 6 1405 1414
90. Antonioli C. M., Danieli E., Airò P., Cattaneo R., Tincani A. More on anticardiolipin and anti-beta2 glycoprotein I in systemic sclerosis. Ann Rheum Dis: 2003; 62 6 589 590
91. Hasegawa M., Sato S., Yanaba K., Komura K., Yamazaki M., Takehara K. Autoantibodies against phosphatidylserine-prothrombin complex in patients with systemic sclerosis. Ann Rheum Dis: 2004; 63 11 1514 1517
92. Koschik R. W. II, Fertig N., Lucas M. R., Domsic R. T., Medsger T. A. Jr. Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol: 2012; 30 (2, Suppl 71): S12 S16
93. Hudson M., Mahler M., Pope J., et al. Clinical Correlates of CENP-A and CENP-B Antibodies in a Large Cohort of Patients with Systemic Sclerosis. J Rheumatol: 2012
94. Fritzler M. J., Hart D. A., Wilson D., et al. Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis. J Rheumatol: 1995; 22 9 1688 1693
95. Grigolo B., Mazzetti I., Meliconi R., et al. Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35. Clin Exp Immunol: 2000; 121 3 539 543
96. Tamby M. C., Chanseaud Y., Humbert M., et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax: 2005; 60 9 765 772
97. Okawa-Takatsuji M., Aotsuka S., Fujinami M., Uwatoko S., Kinoshita M., Sumiya M. Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein. Clin Exp Immunol: 1999; 116 1 174 180
98. Chizzolini C., Raschi E., Rezzonico R., et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum: 2002; 46 6 1602 1613
99. Tamby M. C., Humbert M., Guilpain P., et al. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J: 2006; 28 4 799 807
100. Arnett F. C., Howard R. F., Tan F., et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. Arthritis Rheum: 1996; 39 8 1362 1370
101. Mayes M. D. Scleroderma epidemiology. Rheum Dis Clin North Am: 1996; 22 4 751 764
102. Austin E. D., Loyd J. E., Phillips J. A. III. Genetics of pulmonary arterial hypertension. Semin Respir Crit Care Med: 2009; 30 4 386 398
103. Newman J. H., Wheeler L., Lane K. B., et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med: 2001; 345 5 319 324
104. Morse J., Barst R., Horn E., Cuervo N., Deng Z., Knowles J. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol: 2002; 29 11 2379 2381
105. Tew M. B., Arnett F. C., Reveille J. D., Tan F. K. Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases. Arthritis Rheum: 2002; 46 10 2829 2830
106. Wipff J., Kahan A., Hachulla E., et al. Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford): 2007; 46 4 622 625
107. Dorfmüller P., Humbert M., Perros F., et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol: 2007; 38 6 893 902
108. Overbeek M. J., Vonk M. C., Boonstra A., et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J: 2009; 34 2 371 379
109. McGuire F., Kennelly T., Tillack T., Robbins M. Pulmonary capillary hemangiomatosis associated with CREST syndrome: a case report and review of the literature. Respiration: 2010; 80 5 435 438
110. Gugnani M. K., Pierson C., Vanderheide R., Girgis R. E. Pulmonary edema complicating prostacyclin therapy in pulmonary hypertension associated with scleroderma: a case of pulmonary capillary hemangiomatosis. Arthritis Rheum: 2000; 43 3 699 703
111. Le Pavec J., Humbert M., Mouthon L., Hassoun P. M. Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med: 2010; 181 12 1285 1293
112. Hassoun P. M. Therapies for scleroderma-related pulmonary arterial hypertension. Expert Rev Respir Med: 2009; 3 2 187 196
113. Sgonc R., Gruschwitz M. S., Boeck G., Sepp N., Gruber J., Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum: 2000; 43 11 2550 2562
114. Cerinic M. M., Valentini G., Sorano G. G., et al. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum: 2003; 32 5 285 295
115. Choi J. J., Min D. J., Cho M. L., et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol: 2003; 30 7 1529 1533
116. Riccieri V., Stefanantoni K., Vasile M., et al. Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis. Clin Exp Rheumatol: 2011; 29 (2, Suppl 65): S46 S52
117. Nicolls M. R., Taraseviciene-Stewart L., Rai P. R., Badesch D. B., Voelkel N. F. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J: 2005; 26 6 1110 1118
118. Meadows C. A., Risbano M. G., Zhang L., et al. Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension. Chest: 2011; 139 5 994 1002
119. Saggar R., Saggar R., Aboulhosn J., Belperio J. A., Zisman D. A., Lynch J. P. III. Diagnosis and hemodynamic assessment of pulmonary arterial hypertension. Semin Respir Crit Care Med: 2009; 30 4 399 410
120. Galiè N., Hoeper M. M., Humbert M., et al. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J: 2009; 34 6 1219 1263
121. D'Alonzo G. E., Barst R. J., Ayres S. M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med: 1991; 115 5 343 349
122. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med: 2004; 351 14 1425 1436
123. Fisher M. R., Mathai S. C., Champion H. C., et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum: 2006; 54 9 3043 3050
124. Williams M. H., Handler C. E., Akram R., et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J: 2006; 27 12 1485 1494
125. Allanore Y., Borderie D., Avouac J., et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum: 2008; 58 1 284 291
126. Bezante G. P., Rollando D., Sessarego M., et al. Cardiac magnetic resonance imaging detects subclinical right ventricular impairment in systemic sclerosis. J Rheumatol: 2007; 34 12 2431 2437
127. Hachulla A. L., Launay D., Gaxotte V., et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis: 2009; 68 12 1878 1884
128. Galiè N., Torbicki A., Barst R., et al. Task Force. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J: 2004; 25 24 2243 2278
129. Mukerjee D., St George D., Knight C., et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford): 2004; 43 4 461 466
130. Arcasoy S. M., Christie J. D., Ferrari V. A., et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med: 2003; 167 5 735 740
131. Tei C., Dujardin K. S., Hodge D. O., et al. Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr: 1996; 9 6 838 847
132. Miller D., Farah M. G., Liner A., Fox K., Schluchter M., Hoit B. D. The relation between quantitative right ventricular ejection fraction and indices of tricuspid annular motion and myocardial performance. J Am Soc Echocardiogr: 2004; 17 5 443 447
133. Forfia P. R., Fisher M. R., Mathai S. C., et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med: 2006; 174 9 1034 1041
134. Kiatchoosakun S., Wongvipaporn C., Nanagara R., Hoit B. D. Right ventricular systolic pressure assessed by echocardiography: a predictive factor of mortality in patients with scleroderma. Clin Cardiol: 2011; 34 8 488 493
135. Grünig E., Janssen B., Mereles D., et al. Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation: 2000; 102 10 1145 1150
136. Alkotob M. L., Soltani P., Sheatt M. A., et al. Reduced exercise capacity and stress-induced pulmonary hypertension in patients with scleroderma. Chest: 2006; 130 1 176 181
137. Condliffe R., Radon M., Hurdman J., et al. CT pulmonary angiography combined with echocardiography in suspected systemic sclerosis-associated pulmonary arterial hypertension. Rheumatology (Oxford): 2011; 50 8 1480 1486
138. Schreiber B. E., Valerio C. J., Keir G. J., et al. Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. Arthritis Rheum: 2011; 63 11 3531 3539
139. Meune C., Avouac J., Airò P., et al. Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum: 2011; 63 9 2790 2796
140. Meune C., Avouac J., Wahbi K., et al. Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients. Arthritis Rheum: 2008; 58 6 1803 1809
141. de Groote P., Gressin V., Hachulla E., et al. ItinerAIR-Scleroderma Investigators. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis: 2008; 67 1 31 36
142. Mathai S. C., Bueso M., Hummers L. K., et al. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J: 2010; 35 1 95 104
143. Luo Y. F., Robbins I. M., Karatas M., Brixey A. G., Rice T. W., Light R. W. Frequency of pleural effusions in patients with pulmonary arterial hypertension associated with connective tissue diseases. Chest: 2011; 140 1 42 47
144. Tang K. J., Robbins I. M., Light R. W. Incidence of pleural effusions in idiopathic and familial pulmonary arterial hypertension patients. Chest: 2009; 136 3 688 693
145. Avouac J., Wipff J., Kahan A., Allanore Y. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann Rheum Dis: 2008; 67 6 808 814
146. Pamidi S., Mehta S. Six-minute walk test in scleroderma-associated pulmonary arterial hypertension: are we counting what counts? J Rheumatol: 2009; 36 2 216 218
147. Garin M. C., Highland K. B., Silver R. M., Strange C. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol: 2009; 36 2 330 336
148. Schoindre Y., Meune C., Dinh-Xuan A. T., Avouac J., Kahan A., Allanore Y. Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis. J Rheumatol: 2009; 36 7 1481 1485
149. Vogel-Claussen J., Skrok J., Shehata M. L., et al. Right and left ventricular myocardial perfusion reserves correlate with right ventricular function and pulmonary hemodynamics in patients with pulmonary arterial hypertension. Radiology: 2011; 258 1 119 127
150. Skrok J., Shehata M. L., Mathai S., et al. Pulmonary arterial hypertension: MR imaging-derived first-pass bolus kinetic parameters are biomarkers for pulmonary hemodynamics, cardiac function, and ventricular remodeling. Radiology: 2012; 263 3 678 687
151. Hsu V. M., Moreyra A. E., Wilson A. C., et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol: 2008; 35 3 458 465
152. MacGregor A. J., Canavan R., Knight C., et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford): 2001; 40 4 453 459
153. Humbert M., Sitbon O., Chaouat A., et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med: 2006; 173 9 1023 1030
154. Peacock A. J., Murphy N. F., McMurray J. J., Caballero L., Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J: 2007; 30 1 104 109
155. Sackner M. A., Akgun N., Kimbel P., Lewis D. H. The Pathophysiology of Scleroderma Involving the Heart and Respiratory System. Ann Intern Med: 1964; 60 611 630
156. Salerni R., Rodnan G. P., Leon D. F., Shaver J. A. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med: 1977; 86 4 394 399
157. Ungerer R. G., Tashkin D. P., Furst D., et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med: 1983; 75 1 65 74
158. Stupi A. M., Steen V. D., Owens G. R., Barnes E. L., Rodnan G. P., Medsger T. A. Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum: 1986; 29 4 515 524
159. Murata I., Kihara H., Shinohara S., Ito K. Echocardiographic evaluation of pulmonary arterial hypertension in patients with progressive systemic sclerosis and related syndromes. Jpn Circ J: 1992; 56 10 983 991
160. Battle R. W., Davitt M. A., Cooper S. M., et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest: 1996; 110 6 1515 1519
161. Yamane K., Ihn H., Asano Y., et al. Clinical and laboratory features of scleroderma patients with pulmonary hypertension. Rheumatology (Oxford): 2000; 39 11 1269 1271
162. Chang B., Schachna L., White B., Wigley F. M., Wise R. A. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol: 2006; 33 2 269 274
163. D'Alto M., Ghio S., D'Andrea A., et al. Inappropriate exercise-induced increase in pulmonary artery pressure in patients with systemic sclerosis. Heart: 2011; 97 2 112 117
164. Hachulla E., Coghlan J. G. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis: 2004; 63 9 1009 1014
165. Plastiras S. C., Karadimitrakis S. P., Kampolis C., Moutsopoulos H. M.,
166. Cox S. R., Walker J. G., Coleman M., et al. Isolated pulmonary hypertension in scleroderma. Intern Med J: 2005; 35 1 28 33
167. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis: 2003; 62 2 97 99
168. Ong Y. Y., Nikoloutsopoulos T., Bond C. P., Smith M. D., Ahern M. J., Roberts-Thomson P. J. Decreased nailfold capillary density in limited scleroderma with pulmonary hypertension. Asian Pac J Allergy Immunol: 1998; 16 2-3 81 86
169. Steen V. D., Graham G., Conte C., Owens G., Medsger T. A. Jr. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum: 1992; 35 7 765 770
170. Kawut S. M., Taichman D. B., Archer-Chicko C. L., Palevsky H. I., Kimmel S. E. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest: 2003; 123 2 344 350
171. Mathai S. C., Hummers L. K., Champion H. C., et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum: 2009; 60 2 569 577
172. Koh E. T., Lee P., Gladman D. D., Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol: 1996; 35 10 989 993
173. Chung L., Liu J., Parsons L., et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest: 2010; 138 6 1383 1394
174. Hachulla E., Launay D., Yaici A., et al. French PAH-SSc Network. Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology (Oxford): 2010; 49 5 940 944
175. Thompson A. E., Pope J. E. A study of the frequency of pericardial and pleural effusions in scleroderma. Br J Rheumatol: 1998; 37 12 1320 1323
176. Campo A., Mathai S. C., Le Pavec J., et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med: 2010; 182 2 252 260
177. Forfia P. R., Mathai S. C., Fisher M. R., et al. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med: 2008; 177 12 1364 1369
178. Williams M. H., Das C., Handler C. E., et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart: 2006; 92 7 926 932
179. Fernandes F., Ramires F. J., Arteaga E., Ianni B. M., Bonfá E. S., Mady C. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail: 2003; 9 4 311 317
180. Hinderliter A. L., Willis P. W. IV, Long W., et al. Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. PPH Study Group. Primary pulmonary hypertension. Am J Cardiol: 1999; 84 4 481 484, A10
181. Overbeek M. J., Lankhaar J. W., Westerhof N., et al. Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. Eur Respir J: 2008; 31 6 1160 1166
182. Launay D., Humbert M., Berezne A., et al. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Chest: 2011; 140 4 1016 1024
183. Olschewski H., Ghofrani H. A., Walmrath D., et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med: 1999; 160 2 600 607
184. Le Pavec J., Girgis R. E., Lechtzin N., et al. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum: 2011; 63 8 2456 2464
185. Hinchcliff M., Fischer A., Schiopu E., Steen V. D. PHAROS Investigators Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol: 2011; 38 10 2172 2179
186. Fischer A., Bull T. M., Steen V. D. Practical approach to screening for scleroderma-associated pulmonary arterial hypertension. Arthritis Care Res (Hoboken): 2012; 64 3 303 310
187. Sitbon O., Humbert M., Jaïs X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation: 2005; 111 23 3105 3111
188. Rich S., Kaufmann E., Levy P. S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med: 1992; 327 2 76 81
189. Galiè N., Ussia G., Passarelli P., Parlangeli R., Branzi A., Magnani B. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol: 1995; 75 3 55A 62A
190. Fuster V., Steele P. M., Edwards W. D., Gersh B. J., McGoon M. D., Frye R. L. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation: 1984; 70 4 580 587
191. Kawut S. M., Horn E. M., Berekashvili K. K., et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol: 2005; 95 2 199 203
192. Johnson S. R., Granton J. T., Tomlinson G. A., Grosbein H. A., Hawker G. A., Feldman B. M. Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for Bayesian priors. J Rheumatol: 2011; 38 3 462 469
193. Humbert M., Simonneau G. Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. Nat Clin Pract Rheumatol: 2005; 1 2 93 101
194. Joglekar A., Tsai F. S., McCloskey D. A., Wilson J. E., Seibold J. R., Riley D. J. Bosentan in pulmonary arterial hypertension secondary to scleroderma. J Rheumatol: 2006; 33 1 61 68
195. Girgis R. E., Mathai S. C., Krishnan J. A., Wigley F. M., Hassoun P. M. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant: 2005; 24 10 1626 1631
196. Badesch D. B., Hill N. S., Burgess G., et al. SUPER Study Group. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol: 2007; 34 12 2417 2422
197. Oudiz R. J., Schilz R. J., Barst R. J., et al. Treprostinil Study Group. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest: 2004; 126 2 420 427
198. Kowal-Bielecka O., Landewé R., Avouac J., et al. EUSTAR Co-Authors. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis: 2009; 68 5 620 628
199. McLaughlin V. V., Archer S. L., Badesch D. B., et al. American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol: 2009; 53 17 1573 1619
200. Clements P. J., Tan M., McLaughlin V. V., et al. Pulmonary Arterial Hypertension Quality Enhancement Research Initiative (PAH-QuERI) Investigators. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis: 2012; 71 2 249 252
201. Barst R. J., Rubin L. J., Long W. A., et al. Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med: 1996; 334 5 296 301
202. Simonneau G., Barst R. J., Galie N., et al. Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med: 2002; 165 6 800 804
203. McLaughlin V. V., Gaine S. P., Barst R. J., et al. Treprostinil Study Group. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol: 2003; 41 2 293 299
204. Strauss W. L., Edelman J. D. Prostanoid therapy for pulmonary arterial hypertension. Clin Chest Med: 2007; 28 1 127 142, ix
205. Tapson V. F., Gomberg-Maitland M., McLaughlin V. V., et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest: 2006; 129 3 683 688
206. Kallen A. J., Lederman E., Balaji A., et al. Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol: 2008; 29 4 342 349
207. Hoeper M. M., Galiè N., Simonneau G., Rubin L. J. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med: 2002; 165 9 1209 1216
208. Launay D., Hachulla E., Hatron P. Y., et al. Aerosolized iloprost in CREST syndrome related pulmonary hypertension. J Rheumatol: 2001; 28 10 2252 2256
209. Channick R. N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet: 2001; 358 9288 1119 1123
210. Rubin L. J., Badesch D. B., Barst R. J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med: 2002; 346 12 896 903
211. Denton C. P., Humbert M., Rubin L., Black C. M. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis: 2006; 65 10 1336 1340
212. Galiè N., Olschewski H., Oudiz R. J., et al. Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation: 2008; 117 23 3010 3019
213. Barst R. J., Langleben D., Frost A., et al. STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med: 2004; 169 4 441 447
214. Benza R. L., Mehta S., Keogh A., Lawrence E. C., Oudiz R. J., Barst R. J. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant: 2007; 26 1 63 69
215. Benza R. L., Barst R. J., Galie N., et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest: 2008; 134 4 775 782
216. Valerio C. J., Handler C. E., Kabunga P., Smith C. J., Denton C. P., Coghlan J. G. Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension. Rheumatology (Oxford): 2010; 49 11 2147 2153
217. Rosato E., Molinaro I., Borghese F., Rossi C., Pisarri S., Salsano F. Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension. J Rheumatol: 2010; 37 12 2531 2539
218. Korn J. H., Mayes M., Matucci Cerinic M., et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum: 2004; 50 12 3985 3993
219. Jain M., Varga J. Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers. Expert Opin Pharmacother: 2006; 7 11 1487 1501
220. Matucci-Cerinic M., Denton C. P., Furst D. E., et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis: 2011; 70 1 32 38
221. Galiè N., Ghofrani H. A., Torbicki A., et al. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med: 2005; 353 20 2148 2157
222. Galiè N., Brundage B. H., Ghofrani H. A., et al. Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation: 2009; 119 22 2894 2903
223. O'Callaghan D. S., Gaine S. P. Combination therapy and new types of agents for pulmonary arterial hypertension. Clin Chest Med: 2007; 28 1 169 185, ix
224. Mathai S. C., Girgis R. E., Fisher M. R., et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J: 2007; 29 3 469 475
225. Simonneau G., Rubin L. J., Galiè N., et al. PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med: 2008; 149 8 521 530
226. Keogh A., Strange G., Kotlyar E., et al. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. Intern Med J: 2011; 41 3 235 244
227. Souza R., Sitbon O., Parent F., Simonneau G., Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax: 2006; 61 8 736
228. Ghofrani H. A., Seeger W., Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med: 2005; 353 13 1412 1413
229. Christie J. D., Edwards L. B., Kucheryavaya A. Y., et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report-2011. J Heart Lung Transplant: 2011; 30 10 1104 1122
230. Saggar R., Khanna D., Furst D. E., et al. Systemic sclerosis and bilateral lung transplantation: a single centre experience. Eur Respir J: 2010; 36 4 893 900
231. Schachna L., Medsger T. A. Jr, Dauber J. H., et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum: 2006; 54 12 3954 3961
232. Shitrit D., Amital A., Peled N., et al. Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation. Clin Transplant: 2009; 23 2 178 183
233. Tanoue L. T. Pulmonary hypertension in the collagen vascular diseases. Semin Respir Crit Care Med: 2003; 24 3 287 296
234. Jais X., Launay D., Yaici A., et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum: 2008; 58 2 521 531
235. Launay D., Hachulla E., Hatron P. Y., Jais X., Simonneau G., Humbert M. Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore): 2007; 86 5 299 315